retatrutide phase 2 weight loss a 9-week trip on — LessWrong retatrutide weight loss phase 2

It belongs to a class of medicines known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists

Pending successful completion, FDA approval could come as early as 2027, which would make retatrutide the first approved triple-agonist medication

Tirzepatide represents the most effective GLP-1/GIP therapy currently available through online clinics, offering superior weight loss results compared to other options

Use your symptoms as feedback

Youll inject the drug under the skin of your abdomen, thigh, or upper arm

Current evidence suggests future protocols may include three stages: Initiation Phase 14 mg weekly 812 week metabolic adaptation Active Weight-Loss Phase 612 mg weekly 612 months Maintenance Phase 36 mg weekly If ongoing trials confirm early findings, retatrutide could become one of the most effective pharmacologic interventions for obesity ever developed